Developmental Outcome of Levetiracetam, Its Major Metabolite in Humans, 2-Pyrrolidinone N-Butyric Acid, and Its Enantiomer (R)-α -ethyl-oxo-pyrrolidine Acetamide in a Mouse Model of Teratogenicity

Epilepsia

Volumn 44, Issue 10, 2003, Pages 1280-1288

  Isoherranen, Nina ^a   Spiegelstein, Ofer ^b   Bialer, Meir ^a   Zhang, Jing ^b   Merriweather, Michelle ^b   Yagen, Boris ^a   Roeder, Michael ^d   Triplett, Aleata A ^c   Schurig, Volker ^d   Finnell, Richard H ^b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d TX A/M Univ Syst Hlth Sci Ctr ^*

Author keywords

Anticonvulsant; Congenital anomalies; Epilepsy; Levetiracetam; Piracetam; Skeletal abnormalities; Teratogenicity

Indexed keywords

2 PYRROLIDINONE N BUTYRIC ACID; ALIZARIN RED S; ALPHA ETHYL OXOPYRROLIDINEACETAMIDE; ANTICONVULSIVE AGENT; DRUG METABOLITE; ETIRACETAM; PIRACETAM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SAFETY; DRUG URINE LEVEL; ENANTIOMER; EXPERIMENTAL MODEL; FEMALE; FETUS MALFORMATION; FETUS WEIGHT; GESTATIONAL AGE; HISTOPATHOLOGY; MOUSE; MOUSE STRAIN; NONHUMAN; OUTCOMES RESEARCH; PHALANX HYPOPLASIA; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; SKELETAL MUSCLE; SKELETON MALFORMATION; TERATOGENICITY; URINARY EXCRETION;

ANIMALS; BUTYRATES; DISEASE MODELS, ANIMAL; FEMALE; FETUS; MICE; PIRACETAM; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PYRROLIDINES; PYRROLIDINONES; TERATOGENS;

EID: 0142040806     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2003.21503.x     Document Type: Article

References (37)

1. Bialer M, Johannessen SI, Kupferberg HJ, et al. A progress report on new antiepileptic drugs: a summary of the sixth Eilat conference (EILAT VI). Epilepsy Res 2002;51:31-71.
2. Dooley M, Plosker GL. Levetiracetam: a review of its adjunctive use in the management of partial onset seizures. Drugs 2000;60:871-93.
3. Mitchell TN, Sander JW. Levetiracetam: a new antiepileptic drug for the adjunctive therapy of chronic epilepsy. Drugs Today 2001;37:665-73.
4. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb LO59) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995;14:137-46.
5. Losher W, Honack D. Profile of ucb LO59, a novel anticonvulsant drug, in models of partial and generalized seizures in mice and rats. Eur J Pharmacol 1993;232:147-58.
6. Margineanu DG, Klitgaard H. Levetiracetam: mechanism of action. In: Levy RH, Mattson RH, Meldrum B, et al., eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:419-27.
7. Van Vleymen B, Van Zandijke M. Piracetam in the treatment of myoclonus: an overview. Acta Neurol Belg 1996;96:270-80.
8. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epilepsy Disord 2000;2:99-105.
9. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-58.
10. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiological and experimental findings spanning three decades, II: human studies. Reprod Toxicol 1991;5:301-35.
11. Finnell RH. Genetic differences in susceptibility to anticonvulsant drug-induced developmental defects. Pharmacol Toxicol 1991;69:223-7.
12. Physician's desk reference (PDR). 55th ed. Montvale, NJ: Medical Economics, 2001:3206-9.
13. French J. Use of levetiracetam in special populations. Epilepsia 2001;42(suppl 4):40-3.
14. Beckman DA, Brent RL. Mechanism of known environmental teratogens: drugs and chemicals. Clin Perinatol 1986;13:649-87.
15. Finnell RH, Buehler BA, Kerr BM, et al. Clinical and experimental studies linking oxidative metabolism to phenytoin-induced teratogenesis. Neurology 1992;42(suppl 5):25-31.
16. Bennett GD, Amore BM, Finnell RH, et al. Teratogenicity of carbamazepine-10,11-epoxide and oxcarbazepine in the SWV mouse. J Pharmacol Exp Ther 1996;279:123742.
17. Finnell RH, Bennett GD, Slattery JT, et al. Effect of treatment with phenobarbital and stiripentol on carbamazepine-induced teratogenicity and reactive metabolite formation. Teratology 1995;52:324-32.
18. Parman T, Chen G, Wells PG. Free radical intermediates of phenytoin and related teratogens. J Biol Chem 1999;273:25079-88.
19. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000;85:77-85.
20. Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Disp 1999;27:250-4.
21. Raymond GV, Buehler BA, Finnell RH, et al. Anticonvulsant teratogenesis: possible metabolic basis. Teratology 1995;51:55-6.
22. Buehler BA, Delimont D, van Waes M, et al. Prenatal prediction of risk of the fetal hydantoin syndrome. N Engl J Med 1990;322:1567-72.
23. Isoherranen N, Yagen B, Roeder M, et al. Pharmacokinetics of levetiracetam and its enantiomer (R)-α-ethyl-2-oxo-pyrrolidine acetamide in dogs. Epilepsia 2000;42:825-30.
24. Snell GD, Fekete E, Hummel KP. The relation of mating, ovulation and the estrus smear in the house mouse to the time of day. Anat Rec 1948;76:30-54.
25. Dawson AB. A note on the staining of the skeleton of cleared specimens with Alizarin Red S. Stain Technol 1926;1:123-4.
26. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb LO59) in serum or plasma by high performance liquid chromatography. Ther Drug Monit 1996;18:154-7.
27. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation: a revisit with a decade of progress. Pharm Res 2000;17:1551-7.
28. Finnell RH, Bennett GD, Karras SB, et al. Common hierarchies of susceptibility to the induction of neural tube defects in mouse embryos by valproic acid and its 4-propyl-4-pentenoic acid metabolite. Teratology 1988;38:313-20.
29. Harden C. Safety profile of levetiracetam. Epilepsia 2001;42(suppl 4):36-9.
30. Nau H, Hauck R-S, Ehlers K. Valproic acid-induced neural tube defects in mouse and human: aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol Toxicol 1991;69:310-21.
31. Bojic U, Ehlers K, Ellerbeck U, et al. Studies on the teratogen pharmacophore of valproic acid analogues: evidence of interactions at a hydrophobic center. Eur J Pharmacol 1998;354:289-99.
32. Bennett GD, Lau F, Calvin JA, et al. Phenytoin-induced teratogenesis: a molecular basis for the observed developmental delay during neurulation. Epilepsia 1997;38:415-23.
33. Finnell RH, Shields HE, Taylor SM, et al. Strain differences in phenobarbital-induced teratogenesis in mice. Teratology 1987;35:177-85.
34. Finnell RH, Bennett GD, Mather GG, et al. Effect of stiripentol dose on phenytoin-induced teratogenesis in a mouse model. Reprod Toxicol 1999;13:85-91.
35. Vorhees CV. Behavioral teratogenicity of valproic acid: selective effects on behavior after prenatal exposure to rats. Psychopharmacology 1987;92:173-9.
36. Vorhees CV. Fetal hydantoin syndrome in rats: dose-effect relationships of prenatal phenytoin on postnatal development and behavior. Teratology 1987;35:287-303.
37. Cissoko H, Jonville-Bera AP, Autret-Leca E. New antiepileptic drugs in pregnancy: outcome of 12 exposed pregnancies. Therapie 2002;57:397-401.